A61K 38/105
Bombesin
Official title: {Bombesin; Related peptides}
A61K38/105 (Bombesin) appears on 37 US grants and 43 published applications in this corpus.
Search patents in A61K- Granted patents
- 37
- Published applications
- 43
- Assignees
- 29
- Inventors
- 95
- Latest grant
- 24 Dec 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 2 | 0 |
| 1999 | 2 | 0 |
| 2000 | 1 | 0 |
| 2001 | 2 | 0 |
| 2002 | 1 | 2 |
| 2003 | 1 | 1 |
| 2004 | 0 | 1 |
| 2005 | 1 | 2 |
| 2006 | 1 | 3 |
| 2007 | 1 | 0 |
| 2008 | 1 | 2 |
| 2009 | 0 | 0 |
| 2010 | 1 | 2 |
| 2011 | 0 | 2 |
| 2012 | 3 | 1 |
| 2013 | 2 | 2 |
| 2014 | 0 | 1 |
| 2015 | 2 | 4 |
| 2016 | 1 | 1 |
| 2017 | 1 | 4 |
| 2018 | 0 | 1 |
| 2019 | 2 | 1 |
| 2020 | 2 | 5 |
| 2021 | 1 | 1 |
| 2022 | 2 | 2 |
| 2023 | 1 | 2 |
| 2024 | 2 | 2 |
| 2025 | 0 | 0 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer, infections and autoimmune disorders24 Dec 2024US 12,173,063 B2AvenCell Europe GmbH
- Lyophilized preparation of cytotoxic dipeptides13 Feb 2024US 11,896,668 B2Oncopeptides AB
- Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer infections and autoimmune disorders24 Jan 2023US 11,560,426 B2AvenCell Europe GmbH
- Methods and compositions for inducing differentiation of human brown adipocyte progenitors23 Aug 2022US 11,419,916 B2Energesis Pharmaceuticals, Inc.
- Lyophilized preparation of cytotoxic dipeptides31 May 2022US 11,344,622 B2Oncopeptides AB
- Methods of reducing type 2 cytokine-mediated inflammation using neuromedin peptides25 Jun 2026US 2026/0174829 A1Rutgers, The State University of New Jersey
- Methods and compositions for inducing differentiation of human brown adipocyte progenitors21 Nov 2024US 2024/0382562 A1Energesis Pharmaceuticals, Inc.
- Lyophilized preparation of cytotoxic dipeptides31 Oct 2024US 2024/0358838 A1Oncopeptides AB
- Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer, infections and autoimmune disorders31 Aug 2023US 2023/0272066 A1AvenCell Europe GmbH
- A conjugation linker containing 2,3-diaminosuccinyl group12 Jan 2023US 2023/0010108 A1Hangzhou Dac Biotech Co., Ltd.
Most cited
By later US patents
- Nova- and decapeptides in the preparation of a drug for the treatment of aids44US 5,985,834 AAsta Medica Aktiengesellschaft · 1999
- Solvent/polymer solutions as suspension vehicles35US 8,114,437 B2Intarcia Therapeutics, Inc. · 2012
- Modifying the permeability of physiological barriers34US 6,407,058 B1Eisai Co., Ltd. · 2002
- Solvent/polymer solutions as suspension vehicles32US 8,206,745 B2Intarcia Therapeutics, Inc. · 2012
- Osmotic drug delivery devices containing suspension formulations comprising particles having active agents and nonaqueous single-phase vehicles31US 8,211,467 B2Intarcia Therapeutics, Inc. · 2012